Understanding FDA's Plausible Mechanism Framework For Genetic Medicines

By Karen Potter and Brigid Bondoc

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for very small patient populations, sometimes a single patient, when the underlying genetic cause of disease is known. That scientific progress creates a difficult regulatory question. How can a sponsor demonstrate safety and effectiveness when there are too few patients for a conventional clinical trial?

FDA’s draft guidance on the “plausible mechanism” framework is an important attempt to answer that question. In February 2026, FDA issued draft guidance titled “Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies That Target Specific Genetic Conditions with Known Biological Cause.” The guidance describes how sponsors may support approval or licensure of certain individualized therapies when randomized trials are not feasible because the patient population is extremely small. The comment period has closed, and while FDA has no statutory deadline to finalize the guidance, stakeholders should anticipate that a final version is forthcoming.

For life science companies, academic developers, patient foundations, and investors, the framework is meaningful because it gives shape to a regulatory path that previously looked uncertain. For patient foundations and families at the center of ultra-rare genetic conditions, it carries particular weight because the framework acknowledges the realities of developing therapies for very small populations and offers a more concrete path forward. Jocelyn Duff, Co-founder and Executive Director of CureCMT4J/Talia Duff Foundation, who has spent the last decade driving therapeutic development for her own daughter’s ultra-rare disease, sees the framework as progress, but stressed the need for a more nuanced approach. “We need to look at regulatory frameworks not as a one-size-fits-all, but through the lens of each ultra-rare disorder: What are the strengths of their disease and therapeutic development platform? What are we still missing? How can we approach a ‘plausible mechanism’ differently if we’re not able to directly measure the targeted protein?”

As presently drafted, the proposed framework would not create a shortcut around FDA’s standards. Sponsors still must show that a product is safe, effective, and made with appropriate quality controls. But the framework recognizes that, for some individualized genetic therapies, the evidence package may need to look different, and FDA may be open to more tailored packages where the evidence tells a disciplined and credible story.

What FDA Is Trying To Solve

The conventional approval model often depends on clinical studies involving groups of patients. That model works poorly when a disease affects only a handful of people, or even a single patient, making randomized trials, control groups, and conventional statistical comparisons impractical.

FDA’s plausible mechanism framework is intended for individualized therapies that target specific genetic conditions with a known biological cause. In plain terms, the sponsor would need to show that the patient’s disease is caused by a known genetic problem, that the therapy is designed to address that problem, and that the patient’s outcome can be compared with what would have been expected without treatment.

The guidance identifies genome-editing products and RNA-based therapies, including antisense oligonucleotides, as examples of products that may fit the framework. FDA has also placed the guidance within a broader set of cell and gene therapy initiatives, including recent guidance on genome-editing safety assessment, and FDA’s cellular and gene therapy guidance page reflects a broader policy focus on development pathways for cell and gene therapy products.

Why This Matters For Individualized Genetic Therapies

These therapies raise the regulatory stakes because each product is designed to intervene at a specific point in a patient’s disease biology. The product may vary from patient to patient, but the regulatory question is the same. It is not simply whether the rationale for the therapy sounds reasonable. It is whether the sponsor can connect the rationale to reviewable evidence showing that the product reached its target and that the patient’s outcome improved compared with the expected disease course.

For patient foundations working on ultra-rare genetic conditions, the framework speaks directly to those challenges. Jill Hawkins, Founder and President of the FAM177A1 Research Fund, whose organization supports research for a condition with roughly a dozen known patients worldwide, described the framework as a turning point. “A randomized controlled trial was never a realistic option for us — and for years we operated with the uncomfortable awareness that the conventional approval path wasn’t really designed for programs like ours,” Hawkins said. “The Plausible Mechanism Framework feels like the FDA finally acknowledging that reality. We ran a proteomics study showing reduced detectable FAM177A1 protein in every patient we tested. That finding always felt significant; now there’s a framework that puts a biomarker like that at the center of the evidence package, not the margins. It changes what we’re building toward, and it gives our families something they haven’t had before: a credible path.”

The core value of the framework is that FDA will look for an integrated story. The disease has a known cause. The product is designed to address that cause. The product reaches or affects the intended target. And the patient’s clinical course or biomarker results suggest a meaningful effect compared with the expected course of disease.

For sponsors of individualized genetic therapies, this means the development plan should be built around the mechanism from the beginning, with a clear strategy for demonstrating target engagement, evaluating safety risks, and measuring whether the patient did better than expected. That last point is critical. In a one-patient or very-small-population setting, natural history evidence may become central. A sponsor needs to know what typically happens to patients with the same or a similar condition without treatment.

The Framework Is Flexible, But Not Informal

One of the most important takeaways is that “individualized” does not mean “light touch.” The framework should not be read as a reduced evidentiary standard. FDA is not proposing that individualized therapies can be approved based on a compelling patient story or a theory of benefit alone. The sponsor still needs nonclinical data, clinical safety information, manufacturing controls, and a persuasive effectiveness case.

For genome editing, that evidence may include whether the intended edit occurred and produced the expected biological effect, whether the effect appears durable, whether there were unwanted edits or other safety concerns, and whether the patient’s condition stabilized or improved compared with the expected disease course.

Manufacturing is just as important. Even when a product is individualized, the sponsor must show that it can be designed, produced, tested, released, and delivered with appropriate controls, an area known in regulatory terms as chemistry, manufacturing, and controls, or CMC. For companies building genome-editing or RNA-based platforms, a repeatable CMC approach may become a major business advantage. If FDA is prepared to consider a smaller or more tailored clinical evidence package, the Agency will still need confidence that the product is well defined, reliably manufactured, and suitable for release.

Business Implications For Life Science Companies

The framework may help companies make earlier and more disciplined go/no-go decisions. Before committing significant capital, a sponsor can ask whether the program has the ingredients FDA will expect, including a clearly understood disease mechanism, a strong rationale for the therapy, reliable natural history evidence, a feasible way to show target engagement, and a credible plan for safety monitoring and manufacturing.

Sponsors should also treat CMC as a core issue from the outset, particularly when the sequence or edit may differ from patient to patient. For platform companies, a repeatable CMC approach may become one of the program’s most important assets.

The framework may also increase the strategic value of platforms, positioning companies with repeatable genome-editing, antisense, or RNA-based platforms ahead of those pursuing one product at a time. A key question will be how much evidence from one individualized product can support confidence in another built from the same platform. FDA has not answered that question fully, but its recent focus on leveraging existing knowledge in gene therapy development suggests that platform learning will remain an important theme.

For investors and strategic partners, the framework provides a diligence checklist. The question is not only whether the science is promising, but whether the sponsor can turn that science into reviewable evidence. Programs with weak natural history data, uncertain manufacturing controls, or unclear target-effect measures may carry more risk than their science suggests.

Reimbursement should also be part of the strategy early. FDA approval or licensure is only one hurdle. Therapies designed for very small populations may raise difficult pricing, coverage, and access questions. Sponsors should anticipate payer concerns about durability, outcome measurement, and real-world follow-up.

With that in mind, several practical takeaways should guide sponsor planning:

• Natural history becomes strategic. When randomized trials are not feasible, natural history evidence may become the comparison against which patient outcomes are assessed. Sponsors should consider early investment in registries, retrospective datasets, patient-level records, and prospective observational studies.
• CMC is part of the value proposition. Individualized therapies still need reliable manufacturing and quality controls. If the clinical evidence package is smaller by necessity, FDA may place greater weight on whether the sponsor can show that the product is well characterized, consistently manufactured, appropriately tested, and suitable for release, even where the product sequence or edit varies from patient to patient.
• Platform evidence may become a differentiator. Sponsors with repeatable genome-editing, antisense, or RNA-based platforms may be able to build knowledge across related products or disease variants. The extent to which FDA will allow that knowledge to support confidence in a new individualized therapy remains an important open question.
• FDA engagement should happen early. Sponsors should use meetings to align on whether the program fits the framework, what evidence FDA expects, what endpoints or biomarkers may be meaningful, how natural history comparisons should be constructed, what manufacturing controls are needed, and what long-term follow-up may be required.

Sponsors should not overread the draft guidance. It remains in draft form, and FDA may revise it after reviewing public comments. Important open questions remain, including how FDA will evaluate external controls, how platform evidence may be leveraged, and what post-approval commitments may be expected. Programs that may rely on this framework should begin building natural history evidence, documenting the disease mechanism, pressure-testing manufacturing controls, and seeking early FDA feedback now rather than waiting for the final guidance.

The Bottom Line

FDA’s proposed plausible mechanism framework is best understood as a regulatory bridge. It does not lower the approval standard, but it may make that standard more workable where traditional trials are not feasible. For genome editing, the framework clarifies that sponsors must do more than identify a promising edit. They must connect disease biology, product design, target effect, patient outcome, safety monitoring, and manufacturing quality into a coherent evidence package.

For the life sciences industry, the guidance signals that individualized therapies are moving from exceptional cases toward a more structured development model. The companies best positioned will be those that start early, engage FDA proactively, and build platforms that generate credible evidence across patients, products, and disease variants.

The opportunity is real. So is the burden. For patient foundations and families navigating ultra-rare genetic conditions, the framework represents a meaningful step forward, even as many in the rare disease community believe it does not yet go far enough. As Duff observed, while the framework is a step in the right direction, there remains a need for “more explicit language and interpretation about how this guidance will be used and who will qualify,” noting that “too often, when an ultra-rare disease therapeutic applies for approval, the scientific rigor and ‘flexibility’ used in running and interpreting clinical trials becomes questionable.” The plausible mechanism framework may help bring individualized genetic therapies closer to patients who have few or no options, but realizing that potential will depend on how clearly the framework is applied and how rigorously sponsors and regulators hold the science to account.

About The Authors:

Brigid DeCoursey Bondoc is a partner at Morrison Foerster and leads its FDA + Healthcare Regulatory and Compliance Group. She counsels life sciences companies on a wide range of U.S. Food & Drug Administration pre- and post-market regulatory issues.

Karen Potter is a partner at Morrison Foerster and leads its Cell and Gene Therapy Patent Group. She specializes in patent strategy, prosecution, and portfolio management for biotechnology and pharmaceutical companies worldwide.